SE516067C2 - Användning av en förening för framställning av ett läkemedel - Google Patents
Användning av en förening för framställning av ett läkemedelInfo
- Publication number
- SE516067C2 SE516067C2 SE0000537A SE0000537A SE516067C2 SE 516067 C2 SE516067 C2 SE 516067C2 SE 0000537 A SE0000537 A SE 0000537A SE 0000537 A SE0000537 A SE 0000537A SE 516067 C2 SE516067 C2 SE 516067C2
- Authority
- SE
- Sweden
- Prior art keywords
- group
- positions
- compound
- lower alkyl
- iodine
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 17
- 239000003814 drug Substances 0.000 title claims abstract description 11
- 238000004519 manufacturing process Methods 0.000 title claims description 4
- 238000011282 treatment Methods 0.000 claims abstract description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 10
- 239000001257 hydrogen Substances 0.000 claims abstract description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 6
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 6
- 150000002367 halogens Chemical class 0.000 claims abstract description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 5
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 4
- OIVUHPTVQVCONM-UHFFFAOYSA-N 6-bromo-4-methyl-1h-indazole Chemical compound CC1=CC(Br)=CC2=C1C=NN2 OIVUHPTVQVCONM-UHFFFAOYSA-N 0.000 claims abstract description 3
- 101100294115 Caenorhabditis elegans nhr-4 gene Proteins 0.000 claims abstract description 3
- QZRGKCOWNLSUDK-UHFFFAOYSA-N Iodochlorine Chemical compound ICl QZRGKCOWNLSUDK-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000002253 acid Substances 0.000 claims abstract description 3
- 150000007513 acids Chemical class 0.000 claims abstract description 3
- 125000005055 alkyl alkoxy group Chemical group 0.000 claims abstract description 3
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims abstract description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 3
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims abstract description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims abstract description 3
- 125000001424 substituent group Chemical group 0.000 claims abstract description 3
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 claims abstract description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- NXOVZLREWXNIDP-UHFFFAOYSA-N 7h-pyrazino[2,3-c]carbazole Chemical class N1=CC=NC2=C3C4=CC=CC=C4NC3=CC=C21 NXOVZLREWXNIDP-UHFFFAOYSA-N 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 208000024891 symptom Diseases 0.000 description 10
- 230000000694 effects Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 102000003996 Interferon-beta Human genes 0.000 description 4
- 108090000467 Interferon-beta Proteins 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 229960001388 interferon-beta Drugs 0.000 description 4
- 231100000706 no observed effect level Toxicity 0.000 description 4
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 3
- 102000006386 Myelin Proteins Human genes 0.000 description 2
- 108010083674 Myelin Proteins Proteins 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000009413 insulation Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000005012 myelin Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000004126 nerve fiber Anatomy 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- ZUNBGWZFZVZJHX-UHFFFAOYSA-N 2-(2,3-dimethyl-6h-indolo[2,3-b]quinoxalin-1-yl)-n,n-dimethylethanamine Chemical compound N1C2=NC3=CC=CC=C3C2=NC2=C1C=C(C)C(C)=C2CCN(C)C ZUNBGWZFZVZJHX-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108010072051 Glatiramer Acetate Proteins 0.000 description 1
- 108010005716 Interferon beta-1a Proteins 0.000 description 1
- 108010005714 Interferon beta-1b Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940003504 avonex Drugs 0.000 description 1
- 229940021459 betaseron Drugs 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000007665 chronic toxicity Effects 0.000 description 1
- 231100000160 chronic toxicity Toxicity 0.000 description 1
- 229940038717 copaxone Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 238000011694 lewis rat Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Priority Applications (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0000537A SE516067C2 (sv) | 2000-02-18 | 2000-02-18 | Användning av en förening för framställning av ett läkemedel |
| PCT/SE2001/000326 WO2001060371A1 (fr) | 2000-02-18 | 2001-02-16 | Utilisation d'un compose dans la preparation d'un medicament |
| CNB018052045A CN1192777C (zh) | 2000-02-18 | 2001-02-16 | 吲哚并喹喔啉类化合物用于制备治疗多发性硬化症的药物的用途 |
| AT01908522T ATE269083T1 (de) | 2000-02-18 | 2001-02-16 | Verwendung von indoloquinoxalinen zur behandlung der multiplen sklerose |
| JP2001559467A JP2003522792A (ja) | 2000-02-18 | 2001-02-16 | 薬剤調製用化合物の用途 |
| ES01908522T ES2222981T3 (es) | 2000-02-18 | 2001-02-16 | Uso de indoloquinoxalinas para el tratamiento de esclerosis multiple. |
| AU3626601A AU3626601A (en) | 2000-02-18 | 2001-02-16 | Use of a compound for preparing a drug |
| AU2001236266A AU2001236266B2 (en) | 2000-02-18 | 2001-02-16 | Use of a compound for preparing a drug |
| HU0204547A HUP0204547A3 (en) | 2000-02-18 | 2001-02-16 | Use of indoloquinoxaline derivatives for preparing a drug for treatment of ms |
| DE60103857T DE60103857T2 (de) | 2000-02-18 | 2001-02-16 | Verwendung von indoloquinoxalinen zur behandlung der multiplen sklerose |
| CA002400236A CA2400236C (fr) | 2000-02-18 | 2001-02-16 | Derives d'indoloquinoxaline entrant dans la preparation d'un medicament de traitement de la sclerose en plaques |
| RU2002124771/15A RU2266117C2 (ru) | 2000-02-18 | 2001-02-16 | Применение соединения для получения лекарственного препарата |
| EP01908522A EP1261344B1 (fr) | 2000-02-18 | 2001-02-16 | Utilisation des indoloquinoxalines pour le traitement de la sclerose en plaques |
| NO20023892A NO323783B1 (no) | 2000-02-18 | 2002-08-16 | Anvendelse av en forbindelse for fremstilling av et medikament |
| ZA200206733A ZA200206733B (en) | 2000-02-18 | 2002-08-22 | Use of a compound for preparing a drug. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0000537A SE516067C2 (sv) | 2000-02-18 | 2000-02-18 | Användning av en förening för framställning av ett läkemedel |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| SE0000537D0 SE0000537D0 (sv) | 2000-02-18 |
| SE0000537L SE0000537L (sv) | 2001-08-19 |
| SE516067C2 true SE516067C2 (sv) | 2001-11-12 |
Family
ID=20278504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE0000537A SE516067C2 (sv) | 2000-02-18 | 2000-02-18 | Användning av en förening för framställning av ett läkemedel |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1261344B1 (fr) |
| JP (1) | JP2003522792A (fr) |
| CN (1) | CN1192777C (fr) |
| AT (1) | ATE269083T1 (fr) |
| AU (2) | AU2001236266B2 (fr) |
| CA (1) | CA2400236C (fr) |
| DE (1) | DE60103857T2 (fr) |
| ES (1) | ES2222981T3 (fr) |
| HU (1) | HUP0204547A3 (fr) |
| NO (1) | NO323783B1 (fr) |
| RU (1) | RU2266117C2 (fr) |
| SE (1) | SE516067C2 (fr) |
| WO (1) | WO2001060371A1 (fr) |
| ZA (1) | ZA200206733B (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE527639C2 (sv) * | 2004-06-17 | 2006-05-02 | Oxypharma Ab | Alkylsubstituerade indolokinoxaliner |
| DE602008001795D1 (de) | 2008-04-30 | 2010-08-26 | Univ Duisburg Essen | IndolÄ2,3-bÜ-, IndenÄ1,2-bÜ- und IndenÄ2,1-bÜpyridoÄ2,3-fÜ Quinoxalin-3-Carboxylsäuren und Ester, Verfahren zu ihrer Herstellung und ihre Verwendung als Antivirus- und Antitumormittel |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8600260D0 (sv) * | 1986-01-21 | 1986-01-21 | Lundblad Leif | Substituerade indolokinoxaliner |
-
2000
- 2000-02-18 SE SE0000537A patent/SE516067C2/sv not_active IP Right Cessation
-
2001
- 2001-02-16 CA CA002400236A patent/CA2400236C/fr not_active Expired - Fee Related
- 2001-02-16 AU AU2001236266A patent/AU2001236266B2/en not_active Ceased
- 2001-02-16 JP JP2001559467A patent/JP2003522792A/ja active Pending
- 2001-02-16 RU RU2002124771/15A patent/RU2266117C2/ru active
- 2001-02-16 ES ES01908522T patent/ES2222981T3/es not_active Expired - Lifetime
- 2001-02-16 AU AU3626601A patent/AU3626601A/xx active Pending
- 2001-02-16 DE DE60103857T patent/DE60103857T2/de not_active Expired - Fee Related
- 2001-02-16 AT AT01908522T patent/ATE269083T1/de not_active IP Right Cessation
- 2001-02-16 CN CNB018052045A patent/CN1192777C/zh not_active Expired - Fee Related
- 2001-02-16 WO PCT/SE2001/000326 patent/WO2001060371A1/fr active IP Right Grant
- 2001-02-16 HU HU0204547A patent/HUP0204547A3/hu unknown
- 2001-02-16 EP EP01908522A patent/EP1261344B1/fr not_active Expired - Lifetime
-
2002
- 2002-08-16 NO NO20023892A patent/NO323783B1/no not_active IP Right Cessation
- 2002-08-22 ZA ZA200206733A patent/ZA200206733B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2001236266B2 (en) | 2005-03-17 |
| ES2222981T3 (es) | 2005-02-16 |
| NO323783B1 (no) | 2007-07-09 |
| RU2266117C2 (ru) | 2005-12-20 |
| EP1261344B1 (fr) | 2004-06-16 |
| DE60103857T2 (de) | 2005-07-14 |
| SE0000537D0 (sv) | 2000-02-18 |
| DE60103857D1 (de) | 2004-07-22 |
| SE0000537L (sv) | 2001-08-19 |
| NO20023892L (no) | 2002-08-16 |
| HUP0204547A2 (hu) | 2003-04-28 |
| JP2003522792A (ja) | 2003-07-29 |
| HUP0204547A3 (en) | 2006-01-30 |
| RU2002124771A (ru) | 2004-03-10 |
| CA2400236A1 (fr) | 2001-08-23 |
| WO2001060371A1 (fr) | 2001-08-23 |
| CA2400236C (fr) | 2009-09-22 |
| AU3626601A (en) | 2001-08-27 |
| ATE269083T1 (de) | 2004-07-15 |
| CN1192777C (zh) | 2005-03-16 |
| EP1261344A1 (fr) | 2002-12-04 |
| CN1404393A (zh) | 2003-03-19 |
| ZA200206733B (en) | 2003-08-22 |
| NO20023892D0 (no) | 2002-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Layzer | Myeloneuropathy after prolonged exposure to nitrous oxide | |
| Barash et al. | Saccadic dysmetria and adaptation after lesions of the cerebellar cortex | |
| DE68921760D1 (de) | Behandlung von beschädigtem knochenmark und dosierungseinheiten dafür. | |
| HUP0004412A2 (hu) | Heterociklikus vinil-éterek alkalmazása neurológiai rendellenességek kezelésére szolgáló gyógyszerkészítmények előállítására | |
| HUP0400241A2 (hu) | Hatóanyagként triaza-spiro[5.5]undekán-származékokat tartalmazó gyógyszerkészítmények | |
| DE69828603D1 (de) | Verwendung von a-Glycosylceramiden zur Herstellung eines therapeutischen Mittelszur Behandlung von Autoimmunkrankheiten | |
| EP1471902A1 (fr) | Procede de traitement contre la surdite | |
| TWI230066B (en) | A pharmaceutical composition for treating dry eye | |
| Gentile et al. | Glatiramer acetate protects against inflammatory synaptopathy in experimental autoimmune encephalomyelitis | |
| WO2002089805A2 (fr) | Utilisation d'une therapie de methotrexate intraveineuse, reguliere et a haute dose | |
| Dursun et al. | Antisaccade eye movement abnormalities in Tourette syndrome: evidence for cortico-striatal network dysfunction? | |
| Meagher et al. | Role of supraspinal systems in environmentally induced antinociception: Effect of spinalization and decerebration on brief shock-induced and long shock-induced antinociception. | |
| Leys et al. | Management of focal intracranial infections: is medical treatment better than surgery? | |
| SE516067C2 (sv) | Användning av en förening för framställning av ett läkemedel | |
| Waitz et al. | Aspects of the chronic toxicity of gentamicin sulfate in cats | |
| Hui-Chou et al. | Clinical implications of peripheral myelin protein 22 for nerve compression and neural regeneration: a review | |
| EP0600582A1 (fr) | Traitement de dystrophie musculaire | |
| Felbel et al. | Familial synovial chondromatosis combined with dwarfism | |
| Gücüyener et al. | Co-incidence of Guillain-Barré syndrome and spinal cord compression in non-Hodgkin lymphoma | |
| Lok et al. | Effect of neuregulin-1 on histopathological and functional outcome after controlled cortical impact in mice | |
| US20010046996A1 (en) | Use of a compound for preparing a drug | |
| Yoshioka et al. | Dosage schedule of gentamicin for chronic renal insufficiency in children. | |
| Brandom et al. | Dose-response calculations revisited | |
| Chenijani et al. | Effect of Cinnovex on Patients Suffering from Relapsing-Remitting Multiple Sclerosis | |
| Deeg et al. | Central Nervous System (CNS) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NUG | Patent has lapsed |